Mindset

Over Nine out of 10 Americans Say the Economy and Cost of Living are Having an Impact on Their Family Today

Retrieved on: 
Tuesday, August 9, 2022
Motivation, Mindset, Climate change, Population, Trump, Policy, COVID, Research, Life, Abortion, Review, COVID-19, Family, Gun, Private sector, Adult, Hunting, Census

WASHINGTON, Aug. 9, 2022 /PRNewswire-PRWeb/ -- Economic issues are top concerns now and in the future, but more than half of Americans are most worried about societal issues such as climate change and abortion laws in the long-term.

Key Points: 
  • Climate, guns and abortion are issues of some salience now, but they grow in importance when people think about the future.
  • When asked to select their top issue of concern for the long-term, one-quarter (27%) cite the cost of living and 20% say the U.S. economy.
  • Democrats are as concerned about climate change and abortion laws as they are the economy, and Independents are focused on the cost of living.
  • Four out of ten (41%) say the impact was substantial but life has returned to normal, and for 28% the impact was minimal.

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders

Retrieved on: 
Wednesday, July 6, 2022
Patient, CEO, Otsuka Pharmaceutical, Treatment, Family II, FSE, Family, GLOBE, MSET, CNS, Company, CSE, Psilocybin, CSO, Development, LLC, Patent, Drug discovery, United States Patent and Trademark Office, Pharmaceutical industry, Mindset

Family 2 is included within Mindsets collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies.

Key Points: 
  • Family 2 is included within Mindsets collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds.
  • For further information on Mindset, please visit our website at www.mindsetpharma.com .

Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation

Retrieved on: 
Wednesday, June 29, 2022
Patient, CEO, Otsuka Pharmaceutical, PCT, FSE, Brain, GLOBE, MSET, CNS, CSF, Central nervous system, Company, 5-MeO-DMT, CSE, Plasma, CSO, Development, Pharmacokinetics, POC, Therapy, NCE, Technology, Patent, Central nervous system disease, Drug discovery, Pharmaceutical industry, Mindset

Mindsets novel intranasal formulation technology leverages its unique platform technology, a common feature of several of Mindsets leading psychedelic drug candidates, altering the pharmacokinetics profile of the active pharmaceutical ingredient.

Key Points: 
  • Mindsets novel intranasal formulation technology leverages its unique platform technology, a common feature of several of Mindsets leading psychedelic drug candidates, altering the pharmacokinetics profile of the active pharmaceutical ingredient.
  • The proof of concept (PoC) of this novel formulation demonstrates improved CNS penetration compared to standard formulations of 5-MeO-DMT.
  • Data also demonstrates increased CSF exposure relative to plasma in comparison to a standard formulation by a factor of approximately 3.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin

Retrieved on: 
Wednesday, June 22, 2022
Data, Mental health, Center, Otsuka Pharmaceutical, Neuroscience, University, CEO, CAMH, Company, Brain, American Health, Human, Research, BDNF, CSE, CFOS, Psilocybin, Drug discovery, GLOBE, Addiction, Centre for Addiction and Mental Health, Development, Partnership, FSE, RATS, Patient, MSET, ISCB Senior Scientist Award, Pharmaceutical industry, Medicine, Mindset

Single psychedelic experiences can cause both short- and long-term behavioral changes in humans and the mechanisms of these are relatively under explored.

Key Points: 
  • Single psychedelic experiences can cause both short- and long-term behavioral changes in humans and the mechanisms of these are relatively under explored.
  • The study will interrogate how macro and micro doses of psychedelic compounds modulate expression levels of molecular biomarkers of brain plasticity in rats.
  • This collaboration will profile and build our understanding of the observed superiority of our lead asset, MSP-1014, to psilocybin at the molecular level.
  • This study is the beginning of a strong partnership with CAMH, and we are excited for the research to come.

Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders

Retrieved on: 
Friday, June 10, 2022
CSE, Company, MSET, Otsuka Pharmaceutical, Patent, Pharmacokinetics, CEO, Treatment, Development, Growth, GLOBE, Drug discovery, FSE, Psilocybin, CNS, Safety, Pharmaceutical industry, Mindset

This notice of allowance marks yet another important milestone in our pursuit of creating next generation psychedelic drugs to treat neurological and psychiatric disorders with unmet needs, said James Lanthier, CEO of Mindset Pharma.

Key Points: 
  • This notice of allowance marks yet another important milestone in our pursuit of creating next generation psychedelic drugs to treat neurological and psychiatric disorders with unmet needs, said James Lanthier, CEO of Mindset Pharma.
  • This is a key step towards continued growth for Mindset and our developing pipeline of drug candidates.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma to Participate in Upcoming Conferences in June 2022

Retrieved on: 
Tuesday, June 7, 2022
AC Hotels, CA, CSE, MSET, Conference, Lotte New York Palace Hotel, Otsuka Pharmaceutical, SVP, CEO, Psychedelic drug, Neuropsychiatry, Development, GLOBE, DSM-5, Addiction, Drug discovery, FSE, Electric car, Pharmaceutical industry, Nightclub, Mindset

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that management will participate in three upcoming conferences:

Key Points: 
  • TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that management will participate in three upcoming conferences:
    Grizzle Psychedelics Con 2022 to be held virtually on Wednesday, June 8, 2022.
  • Fiona Randall, SVP, External Alliances and Scientific Strategy of Mindset, will participate in the Commercializing Psychedelics from Hoffmans Bicycle Ride to the Electric Car panel at 1:35 p.m. PT.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

STRONG FIELD PRODUCES A TIE FOR FIRST PLACE IN YOUNG PEOPLE'S MENTAL HEALTH AWARD

Retrieved on: 
Monday, May 30, 2022
Linda, Mindset, Suicide, La Presse, Mental Health Commission of Canada, Mental health, National Helping Families in Mental Health Crisis Day, Sexual misconduct, CBC, Nursing, Association, COVID-19, Canadian Mental Health Association, Depression, The Globe and Mail, Le prix de la liberté, Forum, Canadian Broadcasting Corporation, Toronto Star, Social, University, Organization, Star, Health Canada, Trauma, News, Bengal Film Journalists' Association Awards, Student, COVID, CBC News, Fifth Estate, Globe, Video game, Pharmaceutical industry, Medicine, Nightclub, Animal, Canada Life, Walrus, Violence

MONTREAL, May 30, 2022 /CNW/ - So strong was the field for a new journalism award in the field of young people's mental health, a jury has awarded two equal, full-value first prizes.

Key Points: 
  • MONTREAL, May 30, 2022 /CNW/ - So strong was the field for a new journalism award in the field of young people's mental health, a jury has awarded two equal, full-value first prizes.
  • "The extraordinary interest in the new English and French awards for reporting on the mental health pressures on children, youth and young adults is very encouraging," said Forum president Cliff Lonsdale.
  • The guides are supported by the Mental Health Commission of Canada, with funds from Health Canada.
  • The new Mindset and En-Tte awards for reporting on the mental health of young people, are administered by the Forum and sponsored by the Canadian Mental Health Association.

Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014

Retrieved on: 
Thursday, May 12, 2022
Catalog, Lists of diseases, Company, Contract research organization, FIH, Patient, Otsuka Pharmaceutical, Psilocybin, Family 1, Â, MSET, CSE, CRO, Safety, FSE, Drug discovery, Cancer, Development, CEO, GLOBE, Pharmaceutical industry, Mindset

Recently, the Company engaged a UK-based Contract Research Organization (CRO), Clerkenwell Health , to prepare for an initial scientific meeting with regulators to discuss the companys initial plans for clinical development.

Key Points: 
  • Recently, the Company engaged a UK-based Contract Research Organization (CRO), Clerkenwell Health , to prepare for an initial scientific meeting with regulators to discuss the companys initial plans for clinical development.
  • At Mindset, we are working diligently to advance MSP-1014 through the regulatory process as quickly as possible.
  • We have selected an expert CRO, Clerkenwell Health, to lead the initial scientific discussions with the regulators in the UK as we start to pull together our clinical plans.
  • Were invigorated by this next step and look forward to providing updates along the way, said James Lanthier, CEO of Mindset.

Mindset Pharma to Participate in Upcoming Conferences in May 2022

Retrieved on: 
Wednesday, May 4, 2022
CSO, Drug development, GLOBE, Development, Drug discovery, MSET, CSE, Conference, CEO, FSE, Mental health, Pharmaceutical industry, Nightclub, Mindset

H.C. Wainwright Global Investment Conference to be held at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.

Key Points: 
  • H.C. Wainwright Global Investment Conference to be held at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • The company has a co-development agreement with the McQuade Center for Strategic Research and Development for its short-duration compounds, Mindset Families 2 & 4.

SafeBreach Welcomes Mor Lakritz As Chief Financial Officer

Retrieved on: 
Wednesday, April 27, 2022
People, CEO, IPO, Culture, Mindset, VP, Research, Programming tool, Collection, Leadership, Growth, CISO, Human resources, Robb LaKritz, Hope, Industry, APAC, BAS, SafeBreach, Management, Product

SUNNYVALE, Calif., April 27, 2022 /PRNewswire/ -- SafeBreach, the pioneer in breach and attack simulation (BAS), today announced the addition of industry veteran Mor Lakritz to its executive team as Chief Financial Officer (CFO).

Key Points: 
  • She most recently served as VP, finance at Exabeam and was responsible for all financial, accounting operations and facilities.
  • In her new role, Lakritz will lead SafeBreach's worldwide finance organization as the company continues its global expansion and fast pace growth.
  • "It's an exciting time to join SafeBreach, an industry leader in BAS that offers the most comprehensive coverage against both new and existing cybersecurity threats," said Lakritz.
  • This key hire comes on the heels of other notable promotions, including former Vice President of Product, Yotam Ben Ezra, to Chief Product Officer and former Vice President of Human Resources, Rachel Barouch-Haik, to Chief People Officer.